RxDoctor Payments DataLook up a doctor →

Jaimin Patel, DO

Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1184923708

Payments from drug & device makers

$36,664in general payments, 2019–2025

Across 876 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$7K
  • Mannkind Corporation$6K
  • Amgen$5K
  • Tandem Diabetes Care, Inc.$2K
  • Abbott$2K
  • Lilly USA, LLC$2K
  • plus $12K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cequr Corporation7$7,197
Mannkind Corporation74$6,231
Amgen(2 entities)51$4,857
Tandem Diabetes Care, Inc.17$2,454
Abbott81$2,180
Lilly USA, LLC112$1,857
Medtronic(2 entities)53$1,843
AstraZeneca(2 entities)56$1,290
Insulet Corporation39$1,118
Novo Nordisk54$846
Sanofi-aventis U.S. LLC31$751
Boehringer Ingelheim44$713
Corcept Therapeutics29$689
Xeris Pharmaceuticals, Inc.27$493
Radius Health, Inc.13$354
AbbVie18$301
IBSA Pharma Inc.17$293
Bayer15$290
Valeritas, Inc.16$245
Kyowa Kirin, Inc.5$210
Dexcom, Inc.7$200
Esperion Therapeutics, Inc.4$176
Johnson & Johnson6$171
Antares Pharma, Inc.8$150
Recordati_rare_diseases_inc.7$132
OPKO Pharmaceuticals, LLC6$123
Zealand Pharma US, Inc.6$111
Amneal Pharmaceuticals LLC5$97
Ultragenyx Pharmaceutical Inc.5$85
Novartis4$83
Neurocrine Biosciences, Inc.4$81
Merck6$79
Amarin Pharma, Inc.5$77
Ascensia Diabetes Care US Inc.3$75
Ascendis Pharma Endocrinology Inc4$72
Madrigal Pharmaceuticals2$71
Clarus Therapeutics Inc.5$66
Amryt Pharma Holdings Ltd3$56
Lifescan, Inc.3$55
Scynexis, Inc.2$45
Pfizer2$43
Sequel Med Tech, LLC2$40
BETA Bionics, Inc.1$33
Nevro Corp.1$33
Shire North American Group Inc2$28
Soleno Therapeutics, Inc.1$27
Ipsen Biopharmaceuticals, Inc1$26
Intuity Medical Inc1$26
Rhythm Pharmaceuticals, Inc.1$24
Regeneron Healthcare Solutions, Inc.1$23
Chiesi USA, Inc.1$21
Renalytix AI, Inc.1$18
BD1$17
Acerus Pharmaceuticals Corporation1$17
Astellas Pharma US Inc1$17
Sun Pharmaceutical Industries Inc.1$16
Medicure Pharma Inc.1$15
Kowa Pharmaceuticals America, Inc.1$13
Endo Pharmaceuticals Inc.1$11

How this compares

$36,664 in reported general payments places this provider in the 80th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$155,652
Medicare patients
542
Services billed
1,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →